Martingale Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Martingale Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-16,870	Closed	-$290K	–	786
2023 Q2	$290K	Sell	16,870 -24,102	-59%	-$363K	0.01%	706
2023 Q1	$679K	Sell	40,972 -503	-1%	-$5.87K	0.01%	544
2022 Q4	$316K	Buy	41,475 +100	+0.2%	+$957	0.01%	713
2022 Q3	$412K	Buy	41,375 +1,694	+4%	+$17.6K	0.01%	655
2022 Q2	$361K	Buy	39,681 +14,600	+58%	+$122K	0.01%	710
2022 Q1	$255K	Buy	+25,081	New	+$257K	﹤0.01%	756

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Martingale Asset Management's BBIO Position: Q3 2023 in Review

Martingale Asset Management sold out of BridgeBio Pharma (BBIO) in Q3 2023, closing a stake of 16,870 shares — an estimated $290K sold.

Martingale Asset Management first reported a position in BBIO in Q1 2022 and held it in 6 quarters. The position peaked at $679K in Q1 2023. 221 funds tracked by Wall St. Rank hold BBIO as of Q3 2023.

Martingale Asset Management reported no remaining BridgeBio Pharma position as of Q3 2023 after selling out during the quarter.
Martingale Asset Management sold 16,870 BridgeBio Pharma shares in Q3 2023, an estimated $290K.
Martingale Asset Management first reported a position in BridgeBio Pharma in Q1 2022 and held it in 6 quarters.
Martingale Asset Management's BridgeBio Pharma position peaked at $679K in Q1 2023.
221 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2023.

Based on Martingale Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.